Segments - North America Opioid Market by Products (Codeine, Extended-release/Long-acting, Immediate-release/Short-acting, Oxycodone, Hydrocodone, Morphine, Fentanyl, Hydroxymorphone, Propoxyphene, Oxymorphone, Methadone, Buprenorphine, and Tapentadol), Applications (Cancer Pain, Pain Relief, Post-operative Pain Management, Orthopedic, Low Back Pain, Anesthesia, Fibromyalgia, Neuropathic Pain, Cough Suppression, De-addiction, and Diarrhoea Suppression), and Geography (The US & Canada) - Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
The North America opioid market size was USD 1.92 Billion in 2022 and is likely to reach USD 2.88 Billion by 2031, expanding at a CAGR of 4.6% during 2023–2031. The growth of the market is attributed to the increasing geriatric population and wide popularity of pain management therapies in the region.
Opioids refers to a class of drugs that are widely adopted as pain relievers including anesthesia. The drugs are largely available with medical prescription such as hydrocodone, oxycodone, morphine, codeine and many others. Along with the use as analgesics, the opioids are largely used as anti-diarrheal medicines and cough suppressants. Pain relief medicines are influenced by the non-opioid, as they avoid the risk of developed drug reliance.
Meanwhile, nonsteroidal anti-inflammatory drugs fail to relieve pain when used for a long term as these drugs are distinguished by ceiling effect. Narcotics are prioritized over nonsteroidal as a result. Anti-inflammatory drugs are widely used for long-term treatment of pain management. Affordable Care Act program in 2010 declared that healthcare reforms were launched in the US to convince huge attention and increased funding, to address problems around effective pain management. Several factors such as increasing managed training of healthcare professionals and improved infrastructure for pain management play key roles for the advancement of the market growth.
Growing number of the geriatric population who are at risk of developing irreversible and incurable situations is fueling the demand for pain management therapies. This is expected to boost the market growth.
Rising use of opioid medication for several pain management drugs is a critical element driving the market growth.
Rising penetration of generics along with the increasing healthcare investment phases in the region is estimated to spur the overall market revenue during the forecast period
Presence of strong drug array with efficacious and improved therapeutic drugs are anticipated to further propel the market expansion.
Increasing funding rate to address problems around effective pain management and other R&D activities with supportive government policies are expected to accelerate the market growth.
Misuse of the drugs and issues concerning to drugs abuse are key challenges that can restrict the market growth in the coming years.
The report on the North America opioid market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
North America Opioid Market - Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Products (Codeine, Extended-release/Long-acting, Immediate-release/Short-acting, Oxycodone, Hydrocodone, Morphine, Fentanyl, Hydroxymorphone, Propoxyphene, Oxymorphone, Methadone, Buprenorphine, and Tapentadol) and Applications (Cancer Pain, Pain Relief, Post-operative Pain Management, Orthopedic, Low Back Pain, Anesthesia, Fibromyalgia, Neuropathic Pain, Cough Suppression, De-addiction, and Diarrhoea Suppression) |
Geographical Scope |
The US & Canada |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Allergan Plc (Actavis); Purdue Pharma L.P.; Pfizer, Inc.; Egalet Corp.; and Janssen Pharmaceuticals, Inc. |
Based on products, the North America opioid market is classified into codeine, extended-release/long-acting, immediate-release/short-acting, oxycodone, hydrocodone, morphine, fentanyl, hydroxymorphone, propoxyphene, oxymorphone, methadone, buprenorphine, and tapentado. The oxymorphone segment accounted for a key share of the market in 2019 and is expected to grow at a robust pace during the projected period due to presence of a strong drug pipeline. However, the codeine segment is anticipated to expand at a healthy growth rate during the forecast period owing to the increasing cases of drug abuse involving drugs.
On the basis of applications, the market is divided into cancer pain, pain relief, post-operative pain management, orthopedic, low back pain, anesthesia, fibromyalgia, neuropathic pain, cough suppression, de-addiction, and diarrhea suppression. The anesthesia segment is projected to expand at a considerable CAGR during the forecast period due to large adoption rate and growing awareness among patients. On the other hand, the cancer pain segment is anticipated to expand at substantial growth during the forecast period owing to presence of cancer pain specific drugs and burgeoning incidence rates of cancer.
In terms of geography, the North America opioid market is classified as the US and Canada. The US held a dominant market share in 2019 and is anticipated to constitute a key share of the market during the projected period due to the surging elderly population with a higher prevalence of chronic conditions. Moreover, the wide adoption of advanced techniques for drug development and discovery through extensive research funding present another key driver of the market growth in the country. Meanwhile, the market of Canada is anticipated to exhibit moderate growth during the forecast period owing to the issues related to illegal sales of opioid including OTC products in the country.
The North America opioid market has been segmented on the basis of
Key players competing in the North America opioid market are Allergan Plc (Actavis); Purdue Pharma L.P.; Pfizer, Inc.; Egalet Corp.; and Janssen Pharmaceuticals, Inc. The main market players are continuously engaged in various market expansion activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations to enhance their market share. For instance, Roxane laboratories, Inc. and Boehringer Ingelheim Roxane Inc. were acquired by Hikma Pharmaceuticals Plc in March 2016 to expand its business operations.